Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Region
Library
Years
Person/Organisation
Keywords
  • 1
    UID:
    gbv_1000067394
    Format: 761 S.
    Original writing title: བཀའ་གདམས་རིན་པོ་ཆེའི་གླེགས་བམ་ཕ་ཆོས
    Series Statement: Gangs-can khyad-nor dpe-tshogs
    Note: Text tibet. - Enth.: Jo-bo-rje lha-gcig dpal-ldan Xa-ti-shavi rnam-thar bla-mavi yon-tan chos kyi vbyung-gnas sogs bkav-gdams rin-po-chevi glegs-bam
    Language: Tibetan
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Singapore :Jenny Stanford Publishing,
    UID:
    almahu_9949386421502882
    Format: 1 online resource : , illustrations (some color)
    ISBN: 9781003045410 , 1003045413 , 9781000067385 , 1000067386 , 9781000067408 , 1000067408 , 9781000067392 , 1000067394
    Series Statement: Jenny Stanford Series on Biocatalysis ; volume 7
    Content: Volume 7 of the Jenny Stanford Series on Biocatalysis deals with several different aspects of pharmaceuticals, which include not only various applications of drugs and their metabolism but also natural resources for active pharmaceutical ingredients as well as the removal of pharmaceutical pollution. In detail, novel approaches for developing microbial fermentation processes to produce vitamin B6 using microorganisms are described together with novel routes for vitamin B6 biosynthesis. The other topics discussed are new approaches for producing the successful anticancer drug Taxol from naturally occurring precursors, molecular farming through plant engineering as a cost-effective means to produce therapeutic and prophylactic proteins, and successful screening of potent microorganisms producing L-asparaginase for various chemotherapeutic applications. Furthermore, microbial biotransformations in the production and degradation of fluorinated pharmaceuticals are described. The other chapters inform the reader about the biotransformation of xenobiotics/drugs in living systems, the degradation of pharmaceuticals by white-rot fungi and their ligninolytic enzymes, and the removal of pharmaceutical pollution from municipal sewage using laccase.
    Note: Cover -- Half Title -- Title Page -- Copyright Page -- Table of Contents -- Preface -- Chapter 1: Fermentative Production of Vitamin B6 -- 1.1: Introduction -- 1.2: De novo Synthesis of Vitamin B6 -- 1.3: Control of Vitamin B6 Homeostasis -- 1.4: Engineering Microorganisms for the Production of B6 Vitamers -- 1.5: Novel Routes for Vitamin B6 Biosynthesis and Production -- 1.6: Rational Design and Construction of a Vitamin B6-Producing Bacterium -- 1.7: Alternative Approaches for Enhancing Vitamin B6 Production -- 1.8: Conclusions , Chapter 4: Microbial Biotransformations in the Production and Degradation of Fluorinated Pharmaceuticals -- 4.1: Introduction -- 4.2: Fluorinated Natural Products -- 4.3: Production of Fluorinated Antibiotics in Microorganisms -- 4.4: Biological Production of [18F]-Labelled Compounds for PET Analysis -- 4.5: Microorganisms that Enable Fluorinated Drug Design -- 4.6: Production of Fluorinated Drug Metabolites in Microorganisms -- 4.7: Microbial Degradation of Fluorinated Drugs -- 4.8: Future Prospects and Challenges
    Additional Edition: Print version: Grunwald, Peter. Pharmaceutical Biocatalysis : Drugs, Genetic Diseases, and Epigenetics. Milton : Jenny Stanford Publishing, ©2020 ISBN 9789814877145
    Language: English
    Keywords: Electronic books. ; Electronic books.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Singapore :Jenny Stanford Publishing,
    UID:
    almahu_9949386496702882
    Format: 1 online resource : , illustrations (black and white, and colour).
    ISBN: 9781003045410 , 1003045413 , 9781000067392 , 1000067394 , 9781000067385 , 1000067386 , 9781000067378 , 1000067378 , 9781000067354 , 1000067351 , 9781000067361 , 100006736X , 9781003045397 , 1003045391
    Series Statement: Jenny Stanford series on biocatalysis ; volume 6
    Content: This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
    Note: Cover -- Half Title -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- 1. Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes -- 1.1 Introduction -- 1.2 Hydrolases as Biocatalysts -- 1.2.1 Lipases: A General Account -- 1.2.1.1 Structural features of lipases -- 1.2.1.2 Reaction mechanism of lipases -- 1.2.1.3 Properties of lipases -- 1.2.2 Lipase-Catalyzed Synthesis of Active Pharmaceutical Ingredients and Intermediates -- 1.2.2.1 Non-steroidal antiinflammatory drugs -- 1.2.2.2 Angiotensin-converting enzyme inhibitors , 1.2.2.15 Cathepsin K inhibitor: Odanacatib intermediate -- 1.3 Commercial Success through Green Technologies -- 1.4 Future Perspectives -- 1.4.1 Protein Engineering -- 1.4.2 Directed Evolution -- 1.4.3 Artificial Intelligence -- 1.5 Conclusion -- 2. Phosphodiesterases -- 2.1 Introduction -- 2.2 Classification of PDE Subfamilies -- 2.3 Structural Aspects of Phosphodiesterases -- 2.4 Non-Specific Inhibition of Phosphodiesterases -- 2.5 Phosphodiesterase 3 -- 2.5.1 Structure, Function and Regulation of PDE3 -- 2.5.2 Inhibition of PDE3 -- 2.6 Phosphodiesterase 4 , 2.6.1 Structure, Function and Regulation of PDE4 -- 2.6.2 Inhibition of PDE4 -- 2.7 Phosphodiesterase 5 -- 2.7.1 Structure, Function and Regulation of PDE5 -- 2.7.2 Inhibition of PDE5 -- 2.8 Concluding Remarks -- 3. Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency -- 3.1 Introduction -- 3.2 Structure of DDC -- 3.3 Catalysis of DDC -- 3.4 Drugs Used to Counteract DDC Loss in PD or Loss-of-Function in AADC Deficiency -- 3.5 Conclusions , 4. Advancing Phospholipase D Enzymes as Diverse Drug Targets -- 4.1 Introduction -- 4.2 Non-HKD PLD as a Target for Infectious Diseases and Envenoming -- 4.3 Non-HKD PLD as a Target for Cancer, Inflammatory and Neurodegenerative Diseases -- 4.4 Human PLD Inhibitors Are Potential Drugs for Cancer, Cardiovascular Disease, Infectious Diseases, and Neurodegenerative Diseases -- 4.5 Concluding Remarks -- 5. IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia: Current Perspectives -- 5.1 Introduction -- 5.2 Normal Functions of IDH Enzymes
    Additional Edition: Print version: ISBN 9789814877138
    Language: English
    Keywords: Electronic books. ; Electronic books.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Did you mean 1000007334?
Did you mean 1000047194?
Did you mean 1000027392?
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages